Valdez, B. C., Li, Y., Murray, D., Liu, Y., Nieto, Y., Champlin, R. E., & Andersson, B. S. (2017). The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. Leuk Lymphoma.
Citação norma ChicagoValdez, Benigno C., Yang Li, David Murray, Yan Liu, Yago Nieto, Richard E. Champlin, and Borje S. Andersson. "The PARP Inhibitor Olaparib Enhances the Cytotoxicity of Combined Gemcitabine, Busulfan and Melphalan in Lymphoma Cells." Leuk Lymphoma 2017.
Citação norma MLAValdez, Benigno C., et al. "The PARP Inhibitor Olaparib Enhances the Cytotoxicity of Combined Gemcitabine, Busulfan and Melphalan in Lymphoma Cells." Leuk Lymphoma 2017.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.